[go: up one dir, main page]

AR001996A1 - Compuestos para la inhibicion de la secrecion de acido gastrico, formulaciones farmaceuticas que lo comprenden, su uso para preparar unmedicamento y metodos de tratamiento o profilaxis para enfermedades inflamatorias gastrointestinales. - Google Patents

Compuestos para la inhibicion de la secrecion de acido gastrico, formulaciones farmaceuticas que lo comprenden, su uso para preparar unmedicamento y metodos de tratamiento o profilaxis para enfermedades inflamatorias gastrointestinales.

Info

Publication number
AR001996A1
AR001996A1 ARP950100099A AR10009995A AR001996A1 AR 001996 A1 AR001996 A1 AR 001996A1 AR P950100099 A ARP950100099 A AR P950100099A AR 10009995 A AR10009995 A AR 10009995A AR 001996 A1 AR001996 A1 AR 001996A1
Authority
AR
Argentina
Prior art keywords
treatment
secretion
gastric acid
prophylaxis
inhibition
Prior art date
Application number
ARP950100099A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR001996A1 publication Critical patent/AR001996A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención se refiere a ciertas sales del compuesto 3-butiril-4- (2-metilfenilamino)-8-(2-metilsulfiniletoxi)quinolina, que inhibe exógena oendógenamente la secreción de ácido gástrico estimulada, y que puede por lo tanto usarse para la prevención y tratamiento de enfermedades inflamatoriasgastrointestinales.
ARP950100099A 1994-12-08 1995-11-08 Compuestos para la inhibicion de la secrecion de acido gastrico, formulaciones farmaceuticas que lo comprenden, su uso para preparar unmedicamento y metodos de tratamiento o profilaxis para enfermedades inflamatorias gastrointestinales. AR001996A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/351,852 US5556863A (en) 1993-06-11 1994-12-08 Compound for gastric acid secretion inhibition

Publications (1)

Publication Number Publication Date
AR001996A1 true AR001996A1 (es) 1998-01-07

Family

ID=23382690

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100099A AR001996A1 (es) 1994-12-08 1995-11-08 Compuestos para la inhibicion de la secrecion de acido gastrico, formulaciones farmaceuticas que lo comprenden, su uso para preparar unmedicamento y metodos de tratamiento o profilaxis para enfermedades inflamatorias gastrointestinales.

Country Status (20)

Country Link
US (1) US5556863A (es)
EP (1) EP0796249A1 (es)
JP (1) JPH10510259A (es)
CN (1) CN1169142A (es)
AR (1) AR001996A1 (es)
BR (1) BR9509888A (es)
CA (1) CA2205896A1 (es)
EE (1) EE9700131A (es)
FI (1) FI972410L (es)
HU (1) HUT77949A (es)
IL (1) IL116285A0 (es)
IS (1) IS4485A (es)
MX (1) MX9704136A (es)
NO (1) NO972529L (es)
NZ (1) NZ297566A (es)
PL (1) PL320754A1 (es)
SK (1) SK63797A3 (es)
TR (1) TR199501536A2 (es)
WO (1) WO1996017830A1 (es)
ZA (1) ZA9510066B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042702A (en) * 1973-08-16 1977-08-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Halogen pyrazole derivatives, a method for producing these halogen pyrazole derivatives, medicaments containing and methods of using them
LU69428A1 (es) * 1974-02-20 1975-12-09
US4120972A (en) * 1975-02-03 1978-10-17 Smith Kline & French Laboratories Limited Imidazolylmethylthio-ethyl isothiourea compounds
NO760996L (es) * 1975-03-25 1976-09-28 Byk Gulden Lomberg Chem Fab
AT364354B (de) * 1976-10-14 1981-10-12 Byk Gulden Lomberg Chem Fab Verfahren zur herstellung von neuen pyrazol-1yl-phenylessigsaeuren, deren salzen und optischen isomeren
LU78804A1 (de) * 1977-12-30 1979-07-20 Byk Gulden Lomberg Chem Fab N-substituierte w-aminoalkanoyl-w-aminoalkansaeuren,ihre verwendung und verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US4243678A (en) * 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
YU118379A (en) * 1978-05-24 1983-02-28 Byk Gulden Lomberg Chemischefa Process for preparing phenylaminothiophene acetic acid
US4343804A (en) * 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
AU529934B2 (en) * 1979-08-03 1983-06-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted tetraazatricyclic compounds
EP0024638A1 (en) * 1979-08-30 1981-03-11 Byk Gulden Lomberg Chemische Fabrik GmbH Substituted quinolinone-alkanecarboxylic acids, their preparation, and medicaments containing them
DE3063144D1 (en) * 1979-09-07 1983-06-16 Byk Gulden Lomberg Chem Fab Substituted oxirane carboxylic acids, process for their preparation, their use and medicines containing them
ES496382A0 (es) * 1979-10-31 1982-03-01 Byk Gulden Lomberg Chem Fab Procedimiento para la preparacion de acidos oxocarboxilicos sustituidos
US4381301A (en) * 1980-05-07 1983-04-26 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted tricyclic thieno compounds, their synthesis, their use, their compositions and their medicaments
US4337267A (en) * 1980-08-25 1982-06-29 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids, their use and medicaments containing them
EP0046961B1 (de) * 1980-08-29 1985-02-13 Byk Gulden Lomberg Chemische Fabrik GmbH Epoxi-cycloalkylalkancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung sowie sie enthaltende Arzneimittel
DE3262922D1 (en) * 1981-02-02 1985-05-15 Byk Gulden Lomberg Chem Fab Tricyclic pyrrols, process for their preparation, their use and compositions containing them
FI80022C (fi) * 1982-07-05 1990-04-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av ett nytt, terapeutiskt anvaendbart karbostyrilderivat.
DK585485A (da) * 1984-12-18 1986-08-08 Utsuka Pharm Co Ltd Tetrahydroquinolinderivat, imidazopyridinderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat med mindst en saadan forbindelse
US5250527A (en) * 1985-10-24 1993-10-05 Smithkline & French Laboratories Limited Pyridyl containing benzimidazoles, compositions and use
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
GB8717644D0 (en) * 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
GB8804444D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8804443D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8804448D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8804446D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8804447D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5049567A (en) * 1988-02-25 1991-09-17 Smithkline Beckman Intercredit B.V. Substituted 4-aminoquinazoline derivatives and method of use
GB8804445D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
CA2011086A1 (en) * 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
GB8908229D0 (en) * 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
GB8910722D0 (en) * 1989-05-10 1989-06-28 Smithkline Beckman Intercredit Compounds
DE3917233A1 (de) * 1989-05-26 1990-11-29 Basf Ag 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
GB8918265D0 (en) * 1989-08-10 1989-09-20 Smithkline Beckman Intercredit Compounds
DK0480052T3 (da) * 1990-03-28 1998-05-11 Otsuka Pharma Co Ltd Quinolinderivat, antiulcus-lægemiddel indeholdende derivatet og fremstilling af derivatet
MA22401A1 (fr) * 1991-01-29 1992-10-01 Smithkline Beecham Intercredit Procede de preparation de sels de guinoleine
GB9126438D0 (en) * 1991-12-12 1992-02-12 Smithkline Beecham Intercredit New quinoline derivatives
IS4164A (is) * 1993-06-11 1994-12-12 Ab Astra Efnasambönd sem hindra flæði magasýru

Also Published As

Publication number Publication date
CA2205896A1 (en) 1996-06-13
IL116285A0 (en) 1996-03-31
AU697006B2 (en) 1998-09-24
ZA9510066B (en) 1996-06-10
FI972410A0 (fi) 1997-06-06
PL320754A1 (en) 1997-10-27
NO972529D0 (no) 1997-06-03
BR9509888A (pt) 1997-10-21
AU4274896A (en) 1996-06-26
EP0796249A1 (en) 1997-09-24
SK63797A3 (en) 1998-07-08
JPH10510259A (ja) 1998-10-06
HUT77949A (hu) 1998-12-28
MX9704136A (es) 1998-02-28
CN1169142A (zh) 1997-12-31
FI972410A7 (fi) 1997-06-06
NZ297566A (en) 1998-12-23
FI972410L (fi) 1997-06-06
US5556863A (en) 1996-09-17
IS4485A (is) 1997-05-22
WO1996017830A1 (en) 1996-06-13
EE9700131A (et) 1997-12-15
NO972529L (no) 1997-06-03
TR199501536A2 (tr) 1996-07-21

Similar Documents

Publication Publication Date Title
BR9506029A (pt) Forma farmaêutica oral de múltipla dosagem unitária em tablete processo para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem para o tratamento de doenças inflamatórias gastrointestinais em maniferos e no homem e embalgem de ampola de pressão transversal
MX9308016A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
IL107157A0 (en) Immunopotentiatory agents and pharmaceutical compositions comprising them
BR9909996A (pt) Composto, produtos, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processos para inibir secreção de ácido gástrico, para o tratamento de doenças inflamatórias gastrointestinais, e para o tratamento ou profilaxia de condições que envolvem infecção da mucosa gástrica humana por helicobacter pylori
FI101303B (fi) Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamin o-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino£2,1-a|£2|bentsatsep iini- ja -oksatsino- ja -tiatsino£3,4-a|£2|bentsatsepiini-4-karboksyyl ihappojohdannaisten valmistamiseksi
ES2061252T3 (es) Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
ES2062943B1 (es) Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
DK0662948T3 (da) 2-amino-4-phenyl-4-oxosmørsyrederivater med kynureninase- og/eller kynurenin-3-hydroxylaseinhiberende virkning
SA521421331B1 (ar) تركيبة صيدلانية تشتمل على عامل مضاد للصفيحات ومثبط إفراز حمض معدي
BR9913103A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso do composto, processos para inibir a secreção do ácido gástrico, para o tratamento de doenças inflamatórias gastrointestinal, e para o tratamento ou profilaxia de condições que envolvem a infeção por helicobacter pylori da mucosa gástrica humana, e, formulações farmacêuticas para o uso na inibição da secreção de ácido gástrico, para o uso no tratamento de doenças inflamatórias gastrointestinais, e para o uso no tratamento ou profilaxia de condições que envolvem a infecção por helicobacter pylori da mucosa gástrica humana
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
AR020225A1 (es) Compuestos, productos que los contienen, procesos para su preparacion, formulaciones farmaceuticas, y usos de dichos compuestos
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
MX9308010A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
MX9305510A (es) Compuestos para el tratamiento o profilaxis de desordenes gastrointestinales, cardiovasculares y del sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR001996A1 (es) Compuestos para la inhibicion de la secrecion de acido gastrico, formulaciones farmaceuticas que lo comprenden, su uso para preparar unmedicamento y metodos de tratamiento o profilaxis para enfermedades inflamatorias gastrointestinales.
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
ES2103825T3 (es) Composiciones farmaceuticas que contienen 5-difluorometoxi-2-(3,4-dimetoxi-2-piridil)-metilsulfinil)bencimidazol y un agente anti-helicobacter para el tratamiento de trastornos gastrointestinales.
DE58903964D1 (de) Fluessige orale formulierung.
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
AR030923A1 (es) Sal del enantiomero a del acido carboxilico de 7-cloro-4-(2-oxo-1-fenil-3-pirrolidiniliden)-1,2,3,4-tetrahidro-2-quinolina, forma cristalina, composicion farmaceutica, procedimiento de preparacion, uso en terapia
BR0112690A (pt) Medicamento contendo cilansetron para o tratamento de pacientes ibs masculinos não-obstipativos
MX2022007220A (es) Compuestos y su uso para el tratamiento contra la deficiencia de ¿1- antitripsina.
AR011178A1 (es) Compuesto de sal de sodio de (acido (e) 4,6-dicloro-3-(2-oxo-1- fenilpirrolidin-3-ilideno-metil)-1h-indol-2-carboxilico en su forma hidratada,proceso para su preparacion, composicion farmaceutica que lo contiene y metodo de tratamiento utilizando dicho compuesto